PM
PTLA

Parametrica Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Parametrica Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-17,190
Closed -$123K – 305
2020
Q1 		$123K Buy
+17,190
New +$214K 0.12% 203
2017
Q3 		– Sell
-16,930
Closed -$951K – 462
2017
Q2 		$951K Buy
+16,930
New +$678K 0.89% 2

Other funds holding PTLA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Parametrica Management's PTLA Position: Q2 2020 in Review

Parametrica Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 17,190 shares — an estimated $123K sold.

Parametrica Management first reported a position in PTLA in Q2 2017 and held it in 2 quarters. The position peaked at $951K in Q2 2017. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

  • Parametrica Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Parametrica Management sold 17,190 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $123K.
  • Parametrica Management first reported a position in Portola Pharmaceuticals, Inc. in Q2 2017 and held it in 2 quarters.
  • Parametrica Management's Portola Pharmaceuticals, Inc. position peaked at $951K in Q2 2017.
  • 162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on Parametrica Management's 13F filing for Q2 2020, filed 17 Aug 2020.